American Society of Hirudotherapy

Comparison of outcomes of arterial end-to-side versus end-to-end anastomosis in autologous deep inferior epigastric perforator (DIEP) flap breast reconstruction: DIEP-ES study protocol.

Research article published in International journal of surgery protocols (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsDrug DevelopmentDidzun et al. · International journal of surgery protocols, 2025

Abstract

BACKGROUND: End-to-end anastomosis to the internal mammary artery (IMA) is the current standard anastomosis technique for women undergoing autologous breast reconstruction with deep inferior epigastric perforator (DIEP) flap. This approach fails to preserve the length of the IMA, compromising its availability for cardiac surgery use in women who develop coronary heart disease. A viable alternative may be end-to-side anastomosis, but data on its feasibility is currently lacking. METHODS: This pilot study will involve 60 patients at a single-center institute over approximately 24 months. Inclusion criteria are female sex, age >18 years, history of breast cancer, and eligibility for unilateral autologous DIEP breast reconstruction. Exclusion criteria include patients with a legal guardian, inability to consent, and history of blood clotting disorders or hypercoagulability. Data will be collected at 2 weeks, 6 weeks, 6 months, and 1-year post-surgery. The primary outcome is "major complication" of the recipient site, including anastomotic insufficiency, arterial thrombosis, hematoma, reoperation, or flap loss. Secondary outcomes are abdominal perfusion and major donor site complications, such as wound healing disorders. Patient satisfaction will be assessed using the SF-36 and BREAST-Q (reconstructive module) questionnaires. STUDY STATUS: The DIEP-ES study has begun enrolment in February 2023. As this is an ongoing trial, no results have been gathered yet. The results will be reported upon completion of the study. We anticipate that the primary and secondary outcomes of the end-to-side approach will be comparable to the accepted standard of care, i.e., end-to-end anastomoses. CONCLUSIONS: End-to-side anastomosis may be a safe alternative for DIEP breast reconstruction, especially for patients at risk for coronary heart disease. This pilot study aims to evaluate the feasibility and safety of the end-to-side anastomosis technique in DIEP-flap breast reconstruction. The preliminary findings will inform the design of future multicentric trials to confirm the efficacy of this approach.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

End-to-end anastomosis to the internal mammary artery (IMA) is the current standard anastomosis technique for women undergoing autologous breast reconstruction with deep inferior epigastric perforator (DIEP) flap. This approach fails to preserve the length of the IMA, compromising its availability...

Why This Matters for Hirudotherapy

This article is a study protocol for a planned 60-patient pilot evaluating end-to-side arterial anastomosis in unilateral autologous DIEP flap breast reconstruction, with primary outcomes including major recipient-site complications such as anastomotic insufficiency, arterial thrombosis, hematoma, reoperation, or flap loss; enrollment began in February 2023 and no results were available. The protocol focuses on surgical technique feasibility and safety, and anticipates comparing outcomes with the standard end-to-end approach once complete. It does not mention leeches, hirudotherapy, or the leech secretome. Therefore, it offers no direct evidence for hirudotherapy, and no leech-therapy connection is supported by the abstract.

Citation

Comparison of outcomes of arterial end-to-side versus end-to-end anastomosis in autologous deep inferior epigastric perforator (DIEP) flap breast reconstruction: DIEP-ES study protocol.

Didzun et al. · International journal of surgery protocols, 2025

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.